Related references
Note: Only part of the references are listed.Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression >= 50%
J. F. Gainor et al.
ANNALS OF ONCOLOGY (2020)
Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysis
Chia Ching Lee et al.
ACTA ONCOLOGICA (2020)
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
Francesco Facchinetti et al.
EUROPEAN JOURNAL OF CANCER (2020)
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study
Melissa Bersanelli et al.
BIOMEDICAL REPORTS (2020)
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
Andrea Botticelli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis
Ryul Kim et al.
CLINICAL LUNG CANCER (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Yixin Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Motohiro Tamiya et al.
INVESTIGATIONAL NEW DRUGS (2019)
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
Biagio Ricciuti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
E. J. Aguilar et al.
ANNALS OF ONCOLOGY (2019)
KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer
M. Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Lorenza Landi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices
Vamsidhar Velcheti et al.
IMMUNOTHERAPY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effect of correlation on covariate selection in linear and nonlinear mixed effect models
Peter L. Bonate
PHARMACEUTICAL STATISTICS (2017)
Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas
Sehui Kim et al.
EUROPEAN JOURNAL OF CANCER (2017)
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Jung Han Kim et al.
ONCOTARGET (2017)
The chi-square test for trend
Despina Koletsi et al.
AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
Cesare Gridelli et al.
CLINICAL LUNG CANCER (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Power, selection bias and predictive performance of the population pharmacokinetic covariate model
J Ribbing et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2004)
Share Paper
